

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BUTORPHANO IM	<i>First</i>	6596	27-Mar-2015	1-Apr-2015	<i>USP39–NF34</i>	<i>USP39–NF34</i>	Row 3 of

Monograph Title Section		Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
L TARTRATE NASAL SOLUTION	PUR ITIES/ <i>Organic Impurities</i>	<i>Supplement to USP37–NF32</i>						Column 1 of <i>Table 1</i> : Change 6-Butorphanol to: ?6-Butorphanol
								Line 11 of <i>Analysis</i> : Change C_s = concentration of USP Cisatracurium Besylate RS in the <i>Standard solution</i> to: C_s = concentration of USP Cisatracurium Besylate RS in the <i>Standard solution</i> (mg/mL)
CISATRACURIUM BESYLATE INJECTION	ASSAY/ <i>Procedure</i>	<i>USP38–NF33</i>	2830	27-Mar-2015	1-Apr-2015	<i>USP39–NF34</i>	<i>USP39–NF34</i>	Line 7 of <i>Instrumental conditions</i> : Change 10.0mg, to:
QUETIAPINE TABLETS	PERFORMANCE TESTS/ <i>Dissolution <711>/Test 3</i>	<i>USP38–NF33</i>	5104	27-Mar-2015	1-Apr-2015	<i>USP39–NF34</i>	<i>USP39–NF34</i>	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									100 mg, AND Line 5 of <i>Tolerances:</i> Change <i>For Tablets labeled to contain 100 mg, 200 mg, 300 mg, or 400 mg:</i> to: <i>For Tablets labeled to contain 50 mg, 100 mg, 200 mg, 300 mg, or 400 mg:</i>
MESALAMINE RECTAL SUSPENSION	OTHER COMPONENTS/ <i>Content of Sodium Benzoate (if present)</i>	USP38–NF33	4270	30-Jan-2015		1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Line 5 of <i>Analysis:</i> Change Result = $(r_U/r_S) \times C_S \times (10/W) \times 100$ to: Result = $(r_U/r_S) \times C_S \times (10/W)$
CHLORAMPHE NICOL SODIUM SUCCINATE	<i>Limit of free chloramphenicol</i>	USP37–NF32	2285	30-Jan-2015		1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Line 10 of <i>Chromatographic system:</i> Change Chromatograph

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							the <i>Standard solution</i>, and record the peak areas as directed for <i>Procedure</i>: the relative standard deviation for replicate injections is not less than 2.0%. to: Chromatograph the <i>Standard solution</i>, and record the peak areas as directed for <i>Procedure</i>: the relative standard deviation for replicate injections is not more than 2.0%. Line 13 of <i>Analysis in Test 1</i>: Change
CIPROFLOXACPERFORMANC IN EXTENDED- E RELEASE TESTS/ TABLETS	<i>Revision Bulletin (Official October 01, 2014)</i>	Online	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<711>							M_r2= molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 12 of <i>Analysis in Test 2</i>: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 13 of <i>Analysis in Test</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							3: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
METHOTREXATE IM PURITIES/Organic Impurities/Procedure 1: Related Compounds	USP37–NF32	3762	30-Jan-2015	1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Line 1 of <i>Standard solution A</i> : Change 0.1 ?g/mL of USP Methotrexate RS in <i>Solution A</i> , from the <i>Standard stock solution</i> to: 0.1 µg/mL of USP Methotrexate RS in <i>Solution A</i> , from

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TERAZOSIN TABLETS	PERFORMANCE TESTS/ Dissolution <711>	USP37–NF32	4874	30-Jan-2015		1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Standard stock solution A Line 10 of Analysis: Change M_{r2} = molecular weight of terazosin hydrochloride dihydrate, 459.92 to: M_{r2} = molecular weight of terazosin hydrochloride, 423.89
EXTENDED PHENYTOIN SODIUM CAPSULES	IDENTIFICATION N/A. Infrared Absorption—General <197>	First Supplement to USP37–NF32	6681	30-Jan-2015		1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Line 1 of Sample: Change 6 mg/mL of phenytoin sodium in water from a suitable number of Capsules prepared as follows. Nominally transfer 300 mg of the powder

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BUTABARBITA ASSAY/ L SODIUM <i>Procedure</i> ORAL SOLUTION	USP38–NF33	2500	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	into 50 mL of water in a separator. to: 300 mg of phenytoin sodium from the contents of Capsules in 50 mL of water in a separator. Line 17 of <i>Analysis</i> : Change C_U = nominal concentration of butabarbital sodium in the <i>Sample solution</i> (µg/mL) to: C_U = nominal concentration of butabarbital sodium in the <i>Sample solution</i> (mg/mL)
CITRIC ACID, MAGNESIUM OXIDE, AND SODIUM ASSAY/ <i>Citric Acid</i>	USP38–NF33	2844	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 16 of <i>Analysis</i> : Change

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CARBONATE IRRIGATION							C_U = nominal concentration of citric acid monohydrate in the Assay <i>preparation for citric acid/citrate assay</i> (units/mL) to: C_U = nominal concentration of citric acid monohydrate in the Assay <i>preparation for citric acid/citrate assay</i> (µg/mL)
AZITHROMYCIN IM N PUR ITIES/ <i>Organic Impurities/Procedure 1</i>	USP37–NF32	1886	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 6 of <i>Analysis:</i> Change Calculate the percentages of desosaminylazithromycin and N-demethylazithromycin in the portion of Azithromycin taken:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VALSARTAN AND HYDROCHLOROTHIAZIDE TABLETS	ADDITIONAL REQUIREMENTS	Revision Bulletin (Official S/USP Reference Standards <11>)	Online	30-Jan-2015		1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	to: Calculate the percentages of desosaminylazithromycin, <i>N</i>-demethylazithromycin, and azithromycin A in the portion of Azithromycin taken: Line 2 of USP Valsartan Related Compound B RS: Change (S-<i>N</i>-Butyryl-<i>N</i>-([2?-(1<i>H</i>-tetrazole-5-yl)bi-phen-4-yl]methyl)-valine. to: <i>N</i>-Butyryl-<i>N</i>-{[2?-(1<i>H</i>-tetrazole-5-yl)bi-phenyl-4-yl]methyl}-L-valine.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROGEN PEROXIDE CO NCENTRATE	ASSAY/ <i>Procedure</i>	USP37–NF32	3272	30-Jan-2015		1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 1 of <i>Sample solution</i> : Change 1 mL of Concentrate, diluted to 100 mL to: Weigh about 1 mL of Concentrate in a 100-mL volumetric flask, and dilute with water to volume.
POTASSIUM BITARTRATE	IDENTIFICATION N	USP37–NF32	4346	30-Jan-2015		1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Change <i>C. Identification Tests—General, Tartrate <191></i> to: <i>C. Identification Tests—General, Tartrate <191></i> : Meets the requirements AND Delete subsections: <i>Sample</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ZIPRASIDONE IM HYDROCHLOR PURITIES/ <i>Limit of Tetrahydrofuran</i>	USP37–NF32	5219	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	<i>solution:</i> 1 in 10 solution <i>Acceptance criteria:</i> Meets the requirements Line 1 of <i>Standard solution:</i> Change 0.05 mg/mL of USP Ziprasidone Hydrochloride RS in dimethyl sulfoxide to: 0.05 mg/mL of tetrahydrofuran in dimethyl sulfoxide
AMIODARONE ORGANIC HYDROCHLOR IM IDE PUR ITIES/ <i>Procedure 1/ Chromatographic system</i>	USP38–NF33	2198	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 1 of <i>Adsorbent:</i> Change 0.5-mm layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAFFEINE CITRATE ORAL SOLUTION	ASSAY/ <i>Procedure</i>	USP38–NF33	2521	30-Jan-2015		1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	254 nm to: Suitable layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm Line 5 of Analysis: Change Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2})$
PAROXETINE IM HYDROCHLORIDE	PURITIES/ <i>Limit of 1-Methyl-4-(p-fluorophenyl)-1,2,3,6-tetrahydropyridine</i>	USP38–NF33	4765	30-Jan-2015		1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 1 of Standard solution: Change 42 mg/mL to: 42 ng/mL
ESTRADIOL VAGINAL INSERTS	PERFORMANCE TESTS/ <i>Dissolution <711></i>	USP37–NF32	2866	30-Jan-2015		1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 3 of Analysis: Change Calculate the amount of

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							estradiol (C₁₈H₂₄O₂) dissolved: to: Record the chromatograms, and measure the responses for the estradiol peak. Construct a calibration curve by plotting the peak response versus concentration of the <i>Standard solutions</i>. Determine the amount of estradiol (C₁₈H₂₄O₂) in the <i>Sample solutions</i> from a linear regression analysis of the calibration curve. Calculate the amount of

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CIPROFLOXACIM IN EXTENDED- PUR RELEASE ITIES/ <i>Organic</i> TABLETS <i>Impurities</i>	<i>Revision Bulletin (Official October 01, 2014)</i>	Online	30-Jan-2015	1-Feb-2015	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	estradiol (C ₁₈ H ₂₄ O ₂) dissolved: Line 16 of <i>Analysis:</i> Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 14 of the second Calculate statement in <i>Analysis:</i> Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PACLITAXEL	<i>Related com pounds/Test 2 (for Material Labeled as Produced by a Semisynthetic Process)</i>	USP37–NF32	4163	30-Jan-2015		1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 Line 6 after table in <i>Chromatographic system</i>: Change the relative standard deviation for replicate injections is not more than 2.0%. to: the relative standard deviation for replicate injections is not more than 2.0% for the paclitaxel peak.
TETRACAINE OINTMENT	Assay	USP37–NF32	4891	30-Jan-2015		1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 7 of <i>Procedure</i>: Change (264.37/300.83)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLYCERYL BEHENATE	ASSAY/ Proce dure/ Chromatographi c system	<i>Second Supplement to USP37–NF32</i>	7075	30-Jan-2015	1-Feb-2015	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	(C)(A _U / A _S) to: (264.36/300.82) (C)(A _U / A _S) Line 1 of Column: Change 7.0-mm × 60-cm; 5-μm packing L21 [Note—Two 7.0-mm × 30-cm L21 columns to: 7.5-mm × 60-cm; 5-μm 100-Å packing L21 [Note—Two 7.5-mm × 30-cm L21 columns
BUTABARBITAL SODIUM TABLETS	PERFORMANCE TESTS/ Uniformity of Dosage Units < 905>/Procedure for content uniformity	<i>USP38–NF33</i>	2501	30-Jan-2015	1-Feb-2015	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 18 of Analysis: Change C _U = nominal concentration of butabarbital sodium in the Sample solution

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESCITALOPRAM TABLETS	PERFORMANCE TESTS/ <i>Dissolution</i> <711>/Test 2	USP38–NF33 3364	30-Jan-2015	1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	to: C_U = nominal concentration of butabarbital sodium in the <i>Sample solution</i> (mg/mL) Line 13 of <i>Analysis</i> : Change M_{r2} = molecular weight of escitalopram oxalate, 405.30 to: M_{r2} = molecular weight of escitalopram oxalate, 414.43
AZITHROMYCIN	SPECIFIC TESTS/ <i>pH</i> <791>	USP37–NF32 1886	30-Jan-2015	1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Line 1 of <i>Sample solution</i> : Change 2 mg/mL from the <i>Sample stock solution</i> in a mixture of methanol and water (1:1) to: 2 mg/mL

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CIPROFLOXACASSAY/ IN EXTENDED- <i>Procedure</i> RELEASE TABLETS	<i>Revision Bulletin (Official October 01, 2014)</i>	Online	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	obtained by mixing equal volumes of <i>Sample stock solution</i> and water Line 17 of <i>Analysis</i> : Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
HYOSCYAMIN E SULFATE	<i>USP Reference standards <11></i>	USP37–NF32 3293	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 2 of USP Hyoscyamine Related Compound A RS: Change (1 <i>R</i> ,3 <i>R</i> ,5 <i>S</i>)-8-azabicyclo[3.2.1]oct-3-yl(2 <i>S</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									)-3-hydroxy-2-p henylpropanoat e. to: (1 <i>R</i> ,3 <i>r</i> ,5 <i>S</i>) -8-Azabicyclo[3 .2. 1]oct -3-yl(2 <i>S</i>) -3-hydroxy-2-p henylpropanoat e sulfate (2:1). Change A solution (1 in 10) responds to the tests for <i>Tartrate</i> <191>. to: Responds to the tests for <i>Tartrate</i> <191>.
POTASSIUM SODIUM TARTRATE	<i>Identification/C:</i>	<i>USP37–NF32</i>	4369	30-Jan-2015		1-Feb-2015	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 4: Change NLT 10 ³ cfu/g. to: NMT 10 ³ cfu/g.
RED CLOVER TABLETS	SPECIFIC TESTS/ <i>Microbial Enumeration Tests <2021></i>	<i>USP37–NF32</i>	5526	30-Jan-2015		1-Feb-2015	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 2 of USP Hyoscyamine Related Compound A
ATROPINE SULFATE	ADDITIONAL R EQUIREMENT <i>S/USP Reference</i>	<i>USP38–NF33</i>	2325	30-Jan-2015		1-Feb-2015	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<i>Standards <11></i>							RS: Change Norhyoscyamine sulfate; (1 <i>R</i> ,3 <i>r</i> ,5 <i>S</i>)-8-azabicyclo[3.2.1]octan-3-yl(2 <i>S</i>)-3-hydroxy-2-phenylpropanoate. $C_{16}H_{21}NO_3$ 275.34 to: Norhyoscyamine sulfate; (1 <i>R</i> ,3 <i>r</i> ,5 <i>S</i>)-8-Azabicyclo[3.2.1]octan-3-yl(2 <i>S</i>)-3-hydroxy-2-phenylpropanoate sulfate $(2:1) \cdot (C_{16}H_{21}NO_3)_2 \cdot H_2SO_4$ 648.77 Line 1 of <i>Buffer</i> : Change 0.20 sodium hydroxide
CHLORDIAZEP ASSAY/ OXIDE AND A <i>Procedure</i> MITRIPTYLINE HYDROCHLOR	USP38–NF33	2752	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE TABLETS									to: 0.20 N sodium hydroxide
PAROXETINE HYDROCHLORIDE	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP38–NF33	4765	30-Jan-2015		1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Lines 4 and 7 of USP Paroxetine System Suitability Mixture A RS: Change hydrochloride (3S-trans) to: hydrochloride (3S-trans)
GADOVERSET AMIDE INJECTION	Relaxivity <761>	USP37–NF32	3121	30-Jan-2015		1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Line 1 of Apparatus: Change Use a mini-NMR spectrometer with suitable sensitivity (see Apparatus under Nuclear Magnetic Resonance <761>). to: Use an NMR spectrometer with suitable

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BUPROPION H IM YDROCHLORI PUR DE EXTENDED-ITIES/ <i>Organic</i> RELEASE <i>Impurities</i> TABLETS	<i>Revision Bulletin (Official October 01, 2014)</i>	Online	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	sensitivity. Row 4 of Column 1 of Table 16: Change R,S,S , -Thiomorpholin e derivative ^c to: S,R,R , -Thiomorpholin e derivative ^c
PANCURONIUM BROMIDE ASSAY/ <i>Procedure/ Chromatographic system</i>	USP37–NF32	4176	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 1 of Column: Change 4.6-mm × 250-cm; 5-μm packing L1 to: 4.6-mm × 25-cm; 5-μm packing L1
VALSARTAN TABLETS PERFORMANCE TESTS/ <i>Dissolution <711></i>	USP37–NF32	5116	30-Jan-2015	1-Feb-2015	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 1 of Medium: Change pH 6.8 phosphate buffer; 1000 mL, degassed to: pH 6.8

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RISPERIDONE ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	<i>Second Supplement to USP37–NF32</i>	7240	30-Jan-2015	1-Feb-2015	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	phosphate buffer prepared as follows. Dissolve 6.805 g of monobasic potassium phosphate and 0.896 g of sodium hydroxide in and dilute with water to 1000 mL. Adjust with 0.2 M sodium hydroxide or 1 M phosphoric acid as required to a pH of 6.8; 1000 mL degassed. Line 2 of USP Risperidone Related Compound G RS: Change 3-[2-[4-(4-Fluor o-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							-pyri do[1,2-a]pyrimidin-4-one . C₂₃H₂₈FN₃O₃ 413.49 to: 3-[2-[4-(4-Fluo ro-2-hydroxybe nzoyl)piperidin- 1-yl]ethyl]-2-met hyl-6,7,8,9-tetra hydro-4H -pyri do[1,2-a]pyrimidin-4-one hydrochloride. C₂₃H₂₈FN₃O₃ ·HCl 448.94
CAFFEINE CITRATE INJECTION	ASSAY/ Procedure	USP38–NF33 2520	30-Jan-2015	1-Feb-2015	USP39–NF34	Second Supplement to USP38–NF33	Line 5 of Analysis: Change Result = (r_U/r_S) × C_S × (M_{r1}/M_{r2}) × 100 to: Result = (r_U/r_S) × C_S × (M_{r1}/M_{r2})
CEFUROXIME AXETIL FOR ORAL	ASSAY/ Procedure	USP37–NF32 2243	21-Nov-2014	1-Dec-2014	USP39–NF34	Second Supplement to USP38–NF33	Change Buffer: 23 mg/mL of

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SUSPENSION							monobasic ammonium phosphate in water to: <i>Solution A</i> : 23 g/L of monobasic ammonium phosphate in water AND Line 4 of <i>System suitability solution</i> : Change Dilute with <i>Buffer</i> to volume. to: Dilute with <i>Solution A</i> to volume. AND Line 3 of <i>Standard solution</i> : Change and dilute with <i>Buffer</i> to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GANODERMA LUCIDUM FRUITING BODY POWDER	COMPOSITION	<i>Revision /Content of Triterpenoic Acids</i>	Online	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	volume. to: and dilute with <i>Solution A</i> to volume. AND Line 3 of <i>Sample solution</i>: Change and dilute with <i>Buffer</i> to volume. to: and dilute with <i>Solution A</i> to volume. Line 1 of <i>Standard solution A</i>: Change USP Ganoderic Acid RS to: USP Ganoderic Acid A RS AND Line 3 of variable definition list in <i>Analysis</i>:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									Change r_S = peak area of ganoderic acid in <i>Standard solution A</i> to: r_S = peak area of ganoderic acid A in <i>Standard solution A</i> AND Line 11 of variable definition list in <i>Analysis</i>: Change F = relative response factor, with respect to ganoderic acid A (see <i>Table 3</i>) to: F = relative response factor, with respect to ganoderic acid A (see <i>Table 2</i>) Change: <i>Mobile phase, Resolution</i>
MANNITOL INJECTION	Assay	USP37–NF32	3653	21-Nov-2014		1-Dec-2014	USP39–NF34	Second Supplement to USP38–NF33	

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<i>solution</i>, and <i>Chromatographic system</i> —Proceed as directed in the Assay under <i>Mannitol</i>. to: <i>Mobile phase</i>—Use degassed water. <i>Resolution solution</i> —Dissolve sorbitol and USP Mannitol RS in water to obtain a solution having concentrations of about 4.8 mg per mL of each. <i>Chromatographic system</i> (see <i>Chromatography</i> <621>)—The liquid chromatograph is equipped with

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							a refractive index detector that is maintained at a constant temperature and a 4-mm × 25-cm column that contains packing L19. The column temperature is maintained at a temperature between 30° and 85° controlled within ±2° of the selected temperature, and the flow rate is about 0.5 mL per minute. Chromatograph the <i>Standard preparation</i>, and record the peak responses as directed for <i>Procedure</i>: the relative

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							standard deviation for replicate injections is not more than 2.0%. In a similar manner, chromatograph the <i>Resolution solution</i>: the resolution, <i>R</i>, between the sorbitol and mannitol peaks is not less than 2.0. AND Line 1 of <i>Procedure</i>: Change Proceed as directed for <i>Procedure</i> in the Assay under Mannitol. to: Separately inject equal volumes (about 20 µL) of the Assay

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									preparation and the <i>Standard</i> preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
SACCHARIN SODIUM	IDENTIFICATION/B. Procedure	USP37–NF32	4638	21-Nov-2014		1-Dec-2014	USP39–NF34	Second Supplement to USP38–NF33	Line 1 of Analysis: Change To the <i>Sample solution</i> to: To 10 mL of the <i>Sample solution</i>
ZANAMIVIR	ASSAY/ Procedure/ Chromatographic system	USP37–NF32	5197	21-Nov-2014		1-Dec-2014	USP39–NF34	Second Supplement to USP38–NF33	Line 1 of Column: Change 5-?m packing L## ¹ to: 5-?m packing L82 AND Delete footnote 1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
COPOVIDONE IM	PURITIES/ <i>Limit of Monomers (1-Vinyl-2-Pyrrolidone, Vinyl Acetate, and 2-Pyrrolidone)</i>	USP37–NF32	5938	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 29 of <i>Analysis:</i> Change Calculate the content of 2-pyrrolidinone to: Calculate the content of 2-pyrrolidone
GLYCERYL BEHENATE	DEFINITION	<i>Second Supplement to USP37–NF32</i>	7077	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 7: Change behenic (docosanic) acid to: behenic (docosanoic) acid
METHODS FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS	LIGHT OBSCURATION PARTICLE COUNT TEST/ <i>Instrument Standardization Tests/Particle Counting Accuracy—System Suitability</i>	USP37–NF32	1301	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 11 of <i>Method 2—Multichannel Instruments:</i> Change NMT ±10% of stated size. to: NMT ±10% of stated concentration.
GANODERMA LUCIDUM	COMPOSITION/ <i>Content of</i>	<i>Revision Bulletin (Official</i>	Online	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to</i>	Line 1 of <i>Standard</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FRUITING BODY	<i>Triterpenoic Acids</i>	<i>August 01, 2014)</i>						USP38–NF33	<i>solution A:</i> Change USP Ganoderic Acid RS to: USP Ganoderic Acid A RS AND Line 3 of variable definition list in <i>Analysis:</i> Change r_s = peak area of ganoderic acid in <i>Standard solution A</i> to: r_s = peak area of ganoderic acid A in <i>Standard solution A</i> AND Line 10 of variable definition list in <i>Analysis:</i> Change F = relative response factor,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUTAMIDE	ASSAY/ Procedure	USP37–NF32	3057	21-Nov-2014	1-Dec-2014	USP39–NF34	Second Supplement to USP38–NF33	with respect to ganoderic acid A (see <i>Table 3</i>) to: <i>F</i> = relative response factor, with respect to ganoderic acid A (see <i>Table 2</i>) Line 2 of <i>Sample solution</i> : Change Dissolve the sample in acetonitrile to: Dissolve a previously dried sample in acetonitrile

Pagination

- [First page](#) « [First](#)
- [Previous page](#) < [Previous](#)
- ...
- [Page 26](#)
- [Page 27](#)
- [Page 28](#)
- [Page 29](#)

-
- [_ Page 30](#)
 - [_ Page 31](#)
 - [_ Page 32](#)
 - [_ Page 33](#)
 - [_ Page 34](#)
 - ...
 - [_ Next page Next >](#)
 - [_ Last page Last »](#)